Prophylaxis With Trimethoprim/Sulfamethoxazole Is Not Necessary in Children With Solid Tumors Treated With Low-medium Intensity Chemotherapy

Pediatr Infect Dis J. 2021 Apr 1;40(4):354-355. doi: 10.1097/INF.0000000000003044.

Abstract

Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / standards
  • Antibiotic Prophylaxis / standards*
  • Antibiotic Prophylaxis / statistics & numerical data*
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Child
  • Child, Preschool
  • Humans
  • Immunocompromised Host
  • Neoplasms / drug therapy*
  • Pneumonia, Pneumocystis / microbiology
  • Pneumonia, Pneumocystis / prevention & control*
  • Retrospective Studies
  • Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage*
  • Trimethoprim, Sulfamethoxazole Drug Combination / standards

Substances

  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination